Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29046583 | 0.93 | GAA (0.63) | GAAHTTHPGDALDH1A1KDM4E | |
| SCHEMBL7419408 | 0.87 | GAA (0.74) | GAAHTTHPGDALDH1A1KDM4E | |
| SCHEMBL2793251 | 0.86 | GAA (0.58) | GAAHTTHPGDALDH1A1KDM4E | |
| SCHEMBL8900419 | 0.85 | GAA (0.72) | GAAHTTHPGDALDH1A1KDM4E | |
| SCHEMBL11317879 | 0.85 | GAA (0.72) | GAAHTTHPGDALDH1A1KDM4E | |
| SCHEMBL1743592 | 0.84 | ALDH1A1 (0.51) | GAAHTTHPGDALDH1A1KDM4E | |
| SCHEMBL30463099 | 0.83 | CA12 (0.53) | GAAKDM4ESMN1; SMN2LMNAPOLB | |
| SCHEMBL2726967 | 0.83 | CA12 (0.53) | GAAKDM4ESMN1; SMN2LMNAPOLB | |
| SCHEMBL2650105 | 0.83 | GAA (0.50) | GAAHTTHPGDALDH1A1KDM4E | |
| SCHEMBL4445888 | 0.83 | GAA (0.49) | GAAHTTHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197879-B1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2020-02-26 | — | — | EP | disclosed |
| EP-2934594-B1 | CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . | ALMIRALL SA (ES) | 2019-09-04 | — | — | EP | disclosed |
| CN-106715414-B | With 2 adrenaline excitant of β and the active new bicyclic derivatives of M3 muscarinic antagonist | 阿尔米雷尔有限公司 | 2019-08-30 | — | — | CN | disclosed |
| US-10300072-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2019-05-28 | — | — | US | disclosed |
| US-10005771-B2 | Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2018-06-26 | — | — | US | disclosed |
| US-20180015097-A1 | CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2018-01-18 | — | — | US | disclosed |
| US-20170275277-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2017-09-28 | — | — | US | disclosed |
| US-9757383-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-09-12 | — | — | US | disclosed |
| EP-3197879-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2017-08-02 | — | — | EP | disclosed |
| US-9643961-B2 | Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-05-09 | — | — | US | disclosed |
| WO-2013068554-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2013-05-16 | — | — | WO | disclosed |
| EP-2569308-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2013-03-20 | — | — | EP | disclosed |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | PRAT QUINONES MARIA (ES) | 2013-02-28 | — | — | US | disclosed |
| CN-102892765-A | Novel cyclohexylamine derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL SA | 2013-01-23 | — | — | CN | disclosed |
| WO-2011141180-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2011-11-17 | — | — | WO | disclosed |
| EP-2386555-A1 | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities | Almirall, S.A. (ES) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254356-A1 | Wheel Bearing Apparatus Incorporated With A Wheel Speed Detecting Apparatus | NTN CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-3959477-A | Methods of protection against emesis in mammals by administration of a heterocyclic benzamide | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300072-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ADRB2, CHRM3, CHRM2 | GAA 3739/4885HTT 4220/4885HPGD 1713/4885 |
| US-20170275277-A1 | NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | GAA 3716/4885HTT 4819/4885HPGD 2176/4885 |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | GAA 3262/4885HTT 4537/4885HPGD 2309/4885 |
| US-20180015097-A1 | CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | GAA 3244/4885HTT 4194/4885HPGD 1853/4885 |
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GAA 2875/4885HTT 3934/4885HPGD 339/4885 |
| US-10005771-B2 | Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ADRB2, CHRM3, CHRM2 | GAA 3732/4885HTT 4814/4885HPGD 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.